potassium-permanganate and Cross-Infection

Oral cleansing with chlorhexidine decreases the incidence of nosocomial pneumonia in patients after cardiac surgery. However, evidence of its benefit in ICU patients is conflicting.. Patients admitted to the ICU of an Indian tertiary care teaching hospital were randomized to twice-daily oropharyngeal cleansing with 0.2% chlorhexidine or 0.01% potassium permanganate (control) solution. Effects on the incidence of nosocomial pneumonia during ICU stay (primary outcome) and length of ICU stay and in-hospital mortality (secondary outcomes) were studied.. Five hundred twelve patients were randomized to either the chlorhexidine group (n = 250) or the control group (n = 262). Of the 471 subjects who completed the protocol, nosocomial pneumonia developed in 16 of 224 subjects (7.1%) in the chlorhexidine group and 19 of 247 subjects (7.7%) in the control group (p = 0.82; relative risk, 0.93; 95% confidence interval, 0.49 to 1.76); intention-to-treat analysis of 21 patients in whom the cleansing protocol was not followed revealed similar results. There was no significant difference between the study and control groups in the median day of development of pneumonia (5.0 days: interquartile range [IQR], 3.0 to 7.7 vs 5.0 days: IQR, 3.0 to 6.0, respectively), median ICU stay (5.0 days: IQR, 3.0 to 8.0 vs 6.0 days: IQR, 3.0 to 8.0, respectively), and mortality (34.8% vs 28.3%, respectively). On subgroup analysis, there was no significant difference in the primary and secondary outcomes in patients on mechanical ventilation, tracheal intubation, and coma (Glasgow coma scale

Topics: Administration, Oral; Adult; Anti-Infective Agents, Local; Chlorhexidine; Critical Illness; Cross Infection; Enteral Nutrition; Female; Humans; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Oropharynx; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Potassium Permanganate; Young Adult

In this three-stage study, we test the hypothesis that supplementary cleaning with potassium permanganate > or =4 mg.l(-1) eliminates protein and particle contamination from the reusable Classic laryngeal mask airway. The first stage involved supplementary cleaning of 70 1 x 1 cm segments from deliberately contaminated laryngeal mask airways using potassium permanganate at 0, 2, 4, 8, 16, 32 and 64 mg.l(-1) and testing for protein staining. This showed that the lowest concentration required to eliminate protein contamination was 8 mg.l(-1). The second stage involved supplementary cleaning of 50 used laryngeal mask airways with either potassium permanganate 8 mg.l(-1) or saline and testing for protein staining. This showed that protein contamination was lower in the potassium permanganate group (p < 0.00001): all laryngeal mask airways in the control group and none in the potassium permanganate group were contaminated. The third stage involved scanning electron microscopic examination of 1 x 1 cm segments from three laryngeal mask airways used in the control group, three from the potassium permanganate group, plus three brand new laryngeal mask airways. The mean density of > or =1 mum surface particles was lower in the potassium permanganate 8 mg.l(-1) than the control group (21 vs. 121 .cm(-2), p < 0.0001) and was similar to brand new laryngeal mask airways (24 .cm(-2)). We conclude that supplementary cleaning with potassium permanganate 8 mg.l(-1) eliminates protein deposits from reusable laryngeal mask airways and reduces particle contamination to similar levels to brand new laryngeal mask airways.

Topics: Creutzfeldt-Jakob Syndrome; Cross Infection; Disinfectants; Disinfection; Dose-Response Relationship, Drug; Equipment Contamination; Equipment Reuse; Humans; Laryngeal Masks; Microscopy, Electron, Scanning; Potassium Permanganate; Proteins